Bibliographic Details
| Title: |
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. |
| Authors: |
Pratley, Richard E., Nauck, Michael, Bailey, Timothy, Montanya, Eduard, Cuddihy, Robert, Filetti, Sebastiano, Thomsen, Anne Bloch, Sønderqaard, Rie Elvang, Davies, Melanie |
| Source: |
Lancet. 4/24/2010, Vol. 375 Issue 9724, p1447-1456. 10p. 1 Diagram, 3 Charts, 3 Graphs. |
| Subjects: |
Type 2 diabetes treatment, Drug efficacy, Glucagon-like peptide 1, Clinical drug trials, Hypoglycemic agents, Metformin |
| Abstract: |
The article details a study which investigated the efficacy and safety of human glucagon-like peptide-1 (GLP-1) analogue liraglutide compared to dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin. The study included patients with type 2 diabetes mellitus who have inadequate glycemic control on metformin. It found that liraglutide is more efficient than sitagliptin in terms of lowering HbA1a>. Study authors also found that liraglutide was well tolerated than sitagliptin, and has lower risk for hypoglycemia. They concluded that liraglutide is an effective GLP-1 agent in combination with metformin. |
| Database: |
Psychology and Behavioral Sciences Collection |
